PSMB9

Across TCGA pan-cancer cohorts, PSMB9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PSMB9 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PSMB9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSMB9 expression acts as an unfavorable survival marker.

UCEC, PRAD, and LIHC are the cancer types where PSMB9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
SKCM	DFS	Median	All	0.252	0.737	.045	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PSMB9–UCEC (OS)

Open the UCEC breakdown →